Do analysts prefer GELS or AYTU?

Aytu BioPharma has a consensus target price of $14.50, suggesting a potential upside of 621.39%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aytu BioPharma 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, GELS or AYTU?

Gelteq has higher earnings, but lower revenue than Aytu BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 41.92 -$4.30M N/A N/A Aytu BioPharma $57.57M 0.38 -$14.25M -$1.66 N/A

Do analysts prefer PLRZ or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PLRZ or GELS?

Polyrizon has higher earnings, but lower revenue than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Gelteq $110K 41.92 -$4.30M N/A N/A

Is PLRZ or GELS more profitable?

Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Gelteq N/A N/A N/A

Do analysts prefer UPC or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, UPC or GELS?

Universe Pharmaceuticals has higher revenue and earnings than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 1.15 -$3.67M N/A N/A Gelteq $110K 41.92 -$4.30M N/A N/A

Is UPC or GELS more profitable?

Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Gelteq N/A N/A N/A

Does the media refer more to UPC or GELS?

In the previous week, Gelteq had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 4 mentions for Gelteq and 3 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.68 beat Gelteq's score of 0.60 indicating that Universe Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Universe Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gelteq 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer COCP or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, COCP or GELS?

Gelteq has higher revenue and earnings than Cocrystal Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A Gelteq $110K 41.92 -$4.30M N/A N/A

Is COCP or GELS more profitable?

Gelteq's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Gelteq N/A N/A N/A

Does the media prefer COCP or GELS?

In the previous week, Cocrystal Pharma had 4 more articles in the media than Gelteq. MarketBeat recorded 8 mentions for Cocrystal Pharma and 4 mentions for Gelteq. Cocrystal Pharma's average media sentiment score of 1.07 beat Gelteq's score of 0.60 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gelteq 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZIVO or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ZIVO or GELS?

Gelteq has higher revenue and earnings than ZIVO Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIVO Bioscience $15.85K 1,732.16 -$7.78M -$1.40 N/A Gelteq $110K 41.92 -$4.30M N/A N/A

Is ZIVO or GELS more profitable?

Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Gelteq N/A N/A N/A

Gelteq (GELS) Competitors

$0.43 -0.02 (-4.35%)

Closing price 10/15/2026 03:51 PM Eastern

Extended Trading

$0.44 +0.01 (+1.49%)

As of 09:03 AM Eastern

Compare

GELS vs. AYTU, PLRZ, UPC, COCP, and ZIVO

Should you buy Gelteq stock or one of its competitors? Gelteq's main competitors and comparable companies include Aytu BioPharma (AYTU), Polyrizon (PLRZ), Universe Pharmaceuticals (UPC), Cocrystal Pharma (COCP), and ZIVO Bioscience (ZIVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gelteq compare to Aytu BioPharma?

Gelteq (NASDAQ:GELS) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Gelteq has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Gelteq's return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Aytu BioPharma	-24.76%	-56.54%	-13.14%

Gelteq has higher earnings, but lower revenue than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	41.92	-$4.30M	N/A	N/A
Aytu BioPharma	$57.57M	0.38	-$14.25M	-$1.66	N/A

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gelteq has a beta of -0.41, suggesting that its share price is 141% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Aytu BioPharma has a consensus target price of $14.50, suggesting a potential upside of 621.39%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Aytu BioPharma is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Gelteq had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 4 mentions for Gelteq and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.82 beat Gelteq's score of 0.60 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Gelteq	Positive
Aytu BioPharma	Very Positive

Summary

Aytu BioPharma beats Gelteq on 8 of the 14 factors compared between the two stocks.

How does Gelteq compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon has a beta of -1.2, meaning that its stock price is 220% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

In the previous week, Gelteq had 3 more articles in the media than Polyrizon. MarketBeat recorded 4 mentions for Gelteq and 1 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.82 beat Gelteq's score of 0.60 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Very Positive
Gelteq	Positive

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Gelteq	N/A	N/A	N/A

Polyrizon has higher earnings, but lower revenue than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Gelteq	$110K	41.92	-$4.30M	N/A	N/A

Summary

Gelteq beats Polyrizon on 3 of the 5 factors compared between the two stocks.

How does Gelteq compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Gelteq	N/A	N/A	N/A

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Universe Pharmaceuticals has higher revenue and earnings than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	1.15	-$3.67M	N/A	N/A
Gelteq	$110K	41.92	-$4.30M	N/A	N/A

In the previous week, Gelteq had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 4 mentions for Gelteq and 3 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.68 beat Gelteq's score of 0.60 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Universe Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gelteq	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market.

Summary

Universe Pharmaceuticals beats Gelteq on 6 of the 8 factors compared between the two stocks.

How does Gelteq compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Cocrystal Pharma had 4 more articles in the media than Gelteq. MarketBeat recorded 8 mentions for Cocrystal Pharma and 4 mentions for Gelteq. Cocrystal Pharma's average media sentiment score of 1.07 beat Gelteq's score of 0.60 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gelteq	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market.

6.7% of Cocrystal Pharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Gelteq has higher revenue and earnings than Cocrystal Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Gelteq	$110K	41.92	-$4.30M	N/A	N/A

Gelteq's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Gelteq	N/A	N/A	N/A

Summary

Cocrystal Pharma beats Gelteq on 7 of the 11 factors compared between the two stocks.

How does Gelteq compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.8% of ZIVO Bioscience shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ZIVO Bioscience has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market.

In the previous week, Gelteq had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Gelteq and 0 mentions for ZIVO Bioscience. Gelteq's average media sentiment score of 0.60 beat ZIVO Bioscience's score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Gelteq	Positive

Gelteq has higher revenue and earnings than ZIVO Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,732.16	-$7.78M	-$1.40	N/A
Gelteq	$110K	41.92	-$4.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Gelteq	N/A	N/A	N/A

Summary

Gelteq beats ZIVO Bioscience on 6 of the 10 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.82M	$12.43B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	N/A	670.72	217.88	21.17
Price / Sales	41.92	933.45	624.39	104.67
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	0.40	9.28	10.47	6.01
Net Income	-$4.30M	$2.84B	$3.50B	$380.68M
7 Day Performance	-17.38%	-3.81%	-3.34%	-3.16%
1 Month Performance	-25.78%	-7.00%	-6.60%	-5.20%
1 Year Performance	-66.36%	-4.65%	2.68%	-4.08%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	0.5537 of 5 stars	$0.43 -4.4%	N/A	-66.4%	$4.82M	$110K	N/A	18	Short Interest Increase
AYTU Aytu BioPharma	3.1363 of 5 stars	$2.03 -1.0%	$14.50 +614.3%	-13.4%	$22.01M	$57.57M	N/A	83
PLRZ Polyrizon	1.2421 of 5 stars	$8.99 +1.4%	N/A	+49.0%	$21.83M	N/A	N/A	1	Positive News
UPC Universe Pharmaceuticals	0.9412 of 5 stars	$4.15 -0.7%	N/A	-32.6%	$20.85M	$17.86M	N/A	216	Short Interest Decrease Gap Down
COCP Cocrystal Pharma	2.2467 of 5 stars	$1.07 flat	N/A	-1.9%	$20.61M	N/A	N/A	10	Positive News Short Interest Decrease Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. AYTU, PLRZ, UPC, COCP, and ZIVO

How does Gelteq compare to Aytu BioPharma?

Summary

How does Gelteq compare to Polyrizon?

Summary

How does Gelteq compare to Universe Pharmaceuticals?

Summary

How does Gelteq compare to Cocrystal Pharma?

Summary

How does Gelteq compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. AYTU, PLRZ, UPC, COCP, and ZIVO

How does Gelteq compare to Aytu BioPharma?

Is GELS or AYTU more profitable?

Which has stronger valuation and earnings, GELS or AYTU?

Do insiders & institutionals have more ownership in GELS or AYTU?

Which has more risk and volatility, GELS or AYTU?

Do analysts prefer GELS or AYTU?

Does the media refer more to GELS or AYTU?

Summary

How does Gelteq compare to Polyrizon?

Do analysts prefer PLRZ or GELS?

Which has more risk and volatility, PLRZ or GELS?

Does the media favor PLRZ or GELS?

Is PLRZ or GELS more profitable?

Which has preferable valuation and earnings, PLRZ or GELS?

Summary

How does Gelteq compare to Universe Pharmaceuticals?

Is UPC or GELS more profitable?

Do insiders & institutionals hold more shares of UPC or GELS?

Which has preferable earnings & valuation, UPC or GELS?

Does the media refer more to UPC or GELS?

Do analysts prefer UPC or GELS?

Which has more risk and volatility, UPC or GELS?

Summary

How does Gelteq compare to Cocrystal Pharma?

Does the media prefer COCP or GELS?

Do analysts prefer COCP or GELS?

Which has more risk and volatility, COCP or GELS?

Do institutionals & insiders have more ownership in COCP or GELS?

Which has higher earnings & valuation, COCP or GELS?

Is COCP or GELS more profitable?

Summary

How does Gelteq compare to ZIVO Bioscience?

Do analysts rate ZIVO or GELS?

Do institutionals & insiders believe in ZIVO or GELS?

Which has more volatility & risk, ZIVO or GELS?

Does the media refer more to ZIVO or GELS?

Which has preferable earnings and valuation, ZIVO or GELS?

Is ZIVO or GELS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools